New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Results Confirm that Trilaciclib Reduces Single and Multilineage Grade ≥3 Myelosuppressive Hematologic Adverse Events Including Neutropenia, Anemia, and Thrombocytopenia - - Analyses Showed...
United States Jerome Goldschmidt Us Oncology Network Exchange Commission Globenewswire Inc Investor Relations Corporate Communications
Source: marketscreener.com